ACTG395--INDINAVIR IN COMBINATION W/ STAVUDINE & LAMIVUDINE IN HIV INF CHILDREN

ACTG395--茚地那韦与司他夫定联用

• 批准号: 6264759
• 负责人: RICHARD RUTSTEIN
• 金额: $ 0.06万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264759
• 关键词: AIDS therapy; HIV infections; adolescence (12-20); antiAIDS agent; clinical research; clinical trial phase I; combination chemotherapy; human subject; human therapy evaluation; indinavir; lamivudine; middle childhood (6-11); preschool child (1-5); stavudine

ACTG 395 (and associated protocol Merck 068) evaluates the combination of indinavir (an antiretroviral of the protease inhibitor class) with two nucleoside transcriptase inhibitors (stavudine and lamivudine) in HIV infected children ages 3-18 years. This study closed to accrual of new patients in November, 1998, and we anticipate that treatment and data collection for this study will be extended until at least late 1999 to allow patients to remain on study medications while the FDA reviews the data. No preliminary data are available at this time.

ACTG 395（和相关方案Merck 068）评价了茚地那韦（一种蛋白酶抑制剂类抗逆转录病毒药物）与两种核苷转录酶抑制剂（司他夫定和拉米夫定）联合治疗3-18岁HIV感染儿童的效果。 本研究于1998年11月停止招募新患者，我们预计本研究的治疗和数据收集将至少延长至1999年底，以便在FDA审查数据时允许患者继续使用研究药物。 目前尚无初步数据。